{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:41:14Z","timestamp":1777387274168,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-97827-1","type":"journal-article","created":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T11:04:28Z","timestamp":1745665468000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Modulation of glucose metabolism and insulin resistance following hepatitis C virus clearance via direct-acting antivirals"],"prefix":"10.1038","volume":"15","author":[{"given":"Sajida","family":"Jabeen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramsha","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"May M.","family":"Alrashed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sajjad","family":"Ullah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghulam","family":"Nabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malik Ihsan","family":"Ullah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed Bilal","family":"Waqar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kotb A.","family":"Attia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itoh","family":"Kimiko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,26]]},"reference":[{"key":"97827_CR1","unstructured":"National Hepatitis Elimination Profile for Pakistan. Key Takeaways. https:\/\/www.globalhep.org\/news\/national-hepatitis-elimination-profile-pakistan-key-takeaways#:~:text=Pakistan%20has%20the%20second%20highest,history%20of%20surgery%20(9%25."},{"issue":"1","key":"97827_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","volume":"70","author":"SK Asrani","year":"2019","unstructured":"Asrani, S. K., Devarbhavi, H., Eaton, J. & Kamath, P. S. The burden of liver diseases in the world. J. Hepatol. 70 (1), 151\u2013171. https:\/\/doi.org\/10.1016\/j.jhep.2018.09.014 (2019).","journal-title":"J. Hepatol."},{"issue":"1","key":"97827_CR3","doi-asserted-by":"publisher","first-page":"64","DOI":"10.5604\/01.3001.0010.7536","volume":"17","author":"S Gitto","year":"2018","unstructured":"Gitto, S. et al. Worsening of serum lipid profile after direct acting antiviral treatment. Ann. Hepatol. 17 (1), 64\u201375. https:\/\/doi.org\/10.5604\/01.3001.0010.7536 (2018).","journal-title":"Ann. Hepatol."},{"key":"97827_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.clinbiochem.2018.07.007","volume":"60","author":"GS Lacerda","year":"2018","unstructured":"Lacerda, G. S. et al. Exploring lipid and apolipoprotein levels in chronic hepatitis C patients according to their response to antiviral treatment. Clin. Biochem. 60, 17\u201323. https:\/\/doi.org\/10.1016\/j.clinbiochem.2018.07.007 (2018).","journal-title":"Clin. Biochem."},{"issue":"2","key":"97827_CR5","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41590-020-00817-w","volume":"22","author":"N Hensel","year":"2021","unstructured":"Hensel, N. et al. Memory-like HCV-specific CD8+ T cells retain a molecular Scar after cure of chronic HCV infection. Nat. Immunol. 22 (2), 229\u2013239. https:\/\/doi.org\/10.1038\/s41590-020-00817-w (2021).","journal-title":"Nat. Immunol."},{"issue":"7","key":"97827_CR6","doi-asserted-by":"publisher","first-page":"e0270910","DOI":"10.1371\/journal.pone.0270910","volume":"17","author":"KI Sahibzada","year":"2022","unstructured":"Sahibzada, K. I. et al. Hepatitis C virus transmission cluster among injection drug users in Pakistan. PloS One. 17 (7), e0270910. https:\/\/doi.org\/10.1371\/journal.pone.0270910 (2022).","journal-title":"PloS One"},{"issue":"6","key":"97827_CR7","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1089\/vim.2017.0167","volume":"31","author":"A Zafar","year":"2018","unstructured":"Zafar, A. et al. Prevalence and treatment of untypable HCV variants in different districts of Punjab, Pakistan. Viral Immunol. 31 (6), 426\u2013432. https:\/\/doi.org\/10.1089\/vim.2017.0167 (2018).","journal-title":"Viral Immunol."},{"issue":"9","key":"97827_CR8","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1089\/vim.2019.0058","volume":"32","author":"A Haqqi","year":"2019","unstructured":"Haqqi, A. et al. Prevalence of hepatitis C virus genotypes in Pakistan: current scenario and review of literature. Viral Immunol. 32 (9), 402\u2013413. https:\/\/doi.org\/10.1089\/vim.2019.0058 (2019).","journal-title":"Viral Immunol."},{"issue":"1","key":"97827_CR9","doi-asserted-by":"publisher","first-page":"64","DOI":"10.5604\/01.3001.0010.7536","volume":"17","author":"S Gitto","year":"2018","unstructured":"Gitto, S. et al. Worsening of serum lipid profile after direct acting antiviral treatment. Ann. Hepatol. 17 (1), 64\u201375 (2018).","journal-title":"Ann. Hepatol."},{"issue":"1","key":"97827_CR10","doi-asserted-by":"publisher","first-page":"6836","DOI":"10.1038\/s41467-021-27177-9","volume":"12","author":"LFR Gebert","year":"2021","unstructured":"Gebert, L. F. R., Law, M. & MacRae, I. J. A structured RNA motif locks Argonaute2:miR-122 onto the 5\u2019 end of the HCV genome. Nat. Commun. 12 (1), 6836. https:\/\/doi.org\/10.1038\/s41467-021-27177-9 (2021).","journal-title":"Nat. Commun."},{"issue":"5","key":"97827_CR11","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/s41579-021-00548-1","volume":"19","author":"G Otto","year":"2021","unstructured":"Otto, G. Methylation regulates HCV genome translation. Nat. Rev. Microbiol. 19 (5), 284. https:\/\/doi.org\/10.1038\/s41579-021-00548-1 (2021).","journal-title":"Nat. Rev. Microbiol."},{"key":"97827_CR12","doi-asserted-by":"publisher","first-page":"799382","DOI":"10.3389\/fendo.2021.799382","volume":"12","author":"CH Cheng","year":"2022","unstructured":"Cheng, C. H. et al. Virus elimination by direct-acting antiviral agents impacts glucose homeostasis in chronic hepatitis C patients. Front. Endocrinol. 12, 799382. https:\/\/doi.org\/10.3389\/fendo.2021.799382 (2022).","journal-title":"Front. Endocrinol."},{"issue":"3","key":"97827_CR13","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1590\/S0004-2803.201800000-69","volume":"55","author":"VG Andrade","year":"2018","unstructured":"Andrade, V. G. et al. Insulin resistance reduction after sustained virological response with direct acting antiviral: not every population improves. Arq. Gastroenterol. 55 (3), 274\u2013278. https:\/\/doi.org\/10.1590\/S0004-2803.201800000-69 (2018).","journal-title":"Arq. Gastroenterol."},{"issue":"9","key":"97827_CR14","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.3748\/wjg.v23.i9.1697","volume":"23","author":"AC Desbois","year":"2017","unstructured":"Desbois, A. C. & Cacoub, P. Diabetes mellitus, insulin resistance, and hepatitis C virus infection: A contemporary review. World J. Gastroenterol. 23 (9), 1697\u20131711. https:\/\/doi.org\/10.3748\/wjg.v23.i9.1697 (2017).","journal-title":"World J. Gastroenterol."},{"issue":"4","key":"97827_CR15","doi-asserted-by":"publisher","first-page":"773","DOI":"10.3350\/cmh.2021.0383","volume":"28","author":"HS Shin","year":"2022","unstructured":"Shin, H. S., Jun, B. G. & Yi, S. W. Impact of diabetes, obesity, and dyslipidemia on the risk of hepatocellular carcinoma in patients with chronic liver diseases. Clin. Mol. Hepatol. 28 (4), 773\u2013789. https:\/\/doi.org\/10.3350\/cmh.2021.0383 (2022).","journal-title":"Clin. Mol. Hepatol."},{"key":"97827_CR16","doi-asserted-by":"publisher","first-page":"109870","DOI":"10.1016\/j.diabres.2022.109870","volume":"187","author":"S Ciardullo","year":"2022","unstructured":"Ciardullo, S. et al. Hepatitis C virus infection and diabetes: A complex bidirectional relationship. Diabetes Res. Clin. Pract. 187, 109870. https:\/\/doi.org\/10.1016\/j.diabres.2022.109870 (2022).","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"5","key":"97827_CR17","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1111\/jam.15754","volume":"133","author":"S Younas","year":"2022","unstructured":"Younas, S., Sumrin, A., Hussain, N. & Bilal, M. Identification of NS5B resistance against SOFOSBUVIR in hepatitis C virus genotype 3a, Naive and treated patients. J. Appl. Microbiol. 133 (5), 2826\u20132834. https:\/\/doi.org\/10.1111\/jam.15754 (2022).","journal-title":"J. Appl. Microbiol."},{"key":"97827_CR18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.virusres.2018.02.016","volume":"248","author":"R Bartenschlager","year":"2018","unstructured":"Bartenschlager, R. et al. Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: considerations for scientists and funding agencies. Virus Res. 248, 53\u201362. https:\/\/doi.org\/10.1016\/j.virusres.2018.02.016 (2018).","journal-title":"Virus Res."},{"issue":"12","key":"97827_CR19","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1111\/dom.14168","volume":"22","author":"LE Adinolfi","year":"2020","unstructured":"Adinolfi, L. E. et al. Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antiviral therapy: A prospective study. Diabetes Obes. Metab. 22 (12), 2408\u20132416. https:\/\/doi.org\/10.1111\/dom.14168 (2020).","journal-title":"Diabetes Obes. Metab."},{"issue":"1","key":"97827_CR20","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1053\/jhep.2003.50291","volume":"38","author":"SH Mehta","year":"2003","unstructured":"Mehta, S. H. et al. Hepatitis C virus infection and incident type 2 diabetes. Hepatol. (Baltimore Md). 38 (1), 50\u201356. https:\/\/doi.org\/10.1053\/jhep.2003.50291 (2003).","journal-title":"Hepatol. (Baltimore Md)"},{"issue":"9","key":"97827_CR21","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/j.1365-2036.2009.04094.x","volume":"30","author":"E Tsochatzis","year":"2009","unstructured":"Tsochatzis, E. et al. Serum HCV RNA levels and HCV genotype do not affect insulin resistance in nondiabetic patients with chronic hepatitis C: a multicentre study. Aliment. Pharmacol. Ther. 30 (9), 947\u2013954. https:\/\/doi.org\/10.1111\/j.1365-2036.2009.04094.x (2009).","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"4","key":"97827_CR22","doi-asserted-by":"publisher","first-page":"355","DOI":"10.4065\/75.4.355","volume":"75","author":"H Knobler","year":"2000","unstructured":"Knobler, H., Schihmanter, R., Zifroni, A., Fenakel, G. & Schattner, A. Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. Mayo Clin. Proc. 75 (4), 355\u2013359. https:\/\/doi.org\/10.4065\/75.4.355 (2000).","journal-title":"Mayo Clin. Proc."},{"issue":"2","key":"97827_CR23","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1053\/j.gastro.2007.11.010","volume":"134","author":"R Moucari","year":"2008","unstructured":"Moucari, R. et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 134 (2), 416\u2013423. https:\/\/doi.org\/10.1053\/j.gastro.2007.11.010 (2008).","journal-title":"Gastroenterology"},{"issue":"14","key":"97827_CR24","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1517\/14656566.2011.597742","volume":"12","author":"LE Adinolfi","year":"2011","unstructured":"Adinolfi, L. E., Restivo, L., Zampino, R., Lonardo, A. & Loria, P. Metabolic alterations and chronic hepatitis C: treatment strategies. Expert Opin. Pharmacother. 12 (14), 2215\u20132234. https:\/\/doi.org\/10.1517\/14656566.2011.597742 (2011).","journal-title":"Expert Opin. Pharmacother."},{"issue":"3","key":"97827_CR25","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1586\/eri.09.3","volume":"7","author":"A Lonardo","year":"2009","unstructured":"Lonardo, A., Adinolfi, L. E., Petta, S., Crax\u00ec, A. & Loria, P. Hepatitis C and diabetes: the inevitable coincidence? Expert Rev. anti-infective Therapy. 7 (3), 293\u2013308. https:\/\/doi.org\/10.1586\/eri.09.3 (2009).","journal-title":"Expert Rev. anti-infective Therapy"},{"key":"97827_CR26","unstructured":"Li, J. et al. Impact of sustained virological response on incidence of type 2 diabetes in hepatitis C patients. (2017)."},{"issue":"4","key":"97827_CR27","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1016\/j.dsx.2019.07.032","volume":"13","author":"MB Boraie","year":"2019","unstructured":"Boraie, M. B., Elnaggar, Y. A., Ahmed, M. O. & Mahmoud, A. M. Effect of direct acting antiviral therapy of chronic hepatitis C virus on insulin resistance and Type2 DM in Egyptian patients (prospective study). Diabetes Metabolic Syndrome. 13 (4), 2641\u20132646. https:\/\/doi.org\/10.1016\/j.dsx.2019.07.032 (2019).","journal-title":"Diabetes Metabolic Syndrome"},{"issue":"2","key":"97827_CR28","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/jvh.13215","volume":"27","author":"FP Russo","year":"2020","unstructured":"Russo, F. P. et al. Hepatitis C virus eradication with direct-acting antiviral improves insulin resistance. J. Viral Hepatitis. 27 (2), 188\u2013194. https:\/\/doi.org\/10.1111\/jvh.13215 (2020).","journal-title":"J. Viral Hepatitis"},{"issue":"1","key":"97827_CR29","doi-asserted-by":"publisher","first-page":"17081","DOI":"10.1038\/s41598-019-53051-2","volume":"9","author":"WM Kamp","year":"2019","unstructured":"Kamp, W. M., Sellers, C. M., Stein, S., Lim, J. K. & Kim, H. S. Impact of direct acting antivirals on survival in patients with chronic hepatitis C and hepatocellular carcinoma. Sci. Rep. 9 (1), 17081. https:\/\/doi.org\/10.1038\/s41598-019-53051-2 (2019).","journal-title":"Sci. Rep."},{"issue":"8","key":"97827_CR30","doi-asserted-by":"publisher","first-page":"ofaa308","DOI":"10.1093\/ofid\/ofaa308","volume":"7","author":"M Roelens","year":"2020","unstructured":"Roelens, M. et al. All-cause mortality and causes of death in the Swiss hepatitis C cohort study (SCCS). Open. Forum Infect. Dis. 7 (8), ofaa308. https:\/\/doi.org\/10.1093\/ofid\/ofaa308 (2020).","journal-title":"Open. Forum Infect. Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97827-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97827-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97827-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T11:04:30Z","timestamp":1745665470000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97827-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,26]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["97827"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-97827-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,26]]},"assertion":[{"value":"23 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Declarations"}},{"value":"for the study was obtained from the Ethical Research Committee of the University of Lahore. All the research protocols were evaluated, approved, and carried out according to the Ethical Research Committee guideline. Informed consents were obtained from all the participants before sampling.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14663"}}